Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study

References

• Park JW , Chen M , Colombo M , et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int . 2015;35(9):2155–2166. doi:10.1111/liv.12818 25752327
   PubMed Web of Science ®Google Scholar
• Yang JD , Hainaut P , Gores GJ , Amadou A , Plymoth A , Roberts LR . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol . 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y 31439937
   PubMed Web of Science ®Google Scholar
• Forner A , Reig M , Bruix J . Hepatocellular carcinoma. Lancet . 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2 29307467
   PubMed Web of Science ®Google Scholar
• Kudo M , Finn RS , Qin S , et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet . 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1 29433850
   PubMed Web of Science ®Google Scholar
• Qin S , Ren Z , Meng Z , et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol . 2020;21(4):571–580. doi:10.1016/S1470-2045(20)30011-5 32112738
   PubMed Web of Science ®Google Scholar
• Finn RS , Ikeda M , Zhu AX , Sung MW , Llovet JM . Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol . 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808 32716739
   PubMed Web of Science ®Google Scholar
• Hou J , Wang G , Wang F , et al. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol . 2017;5(4):297–318. doi:10.14218/JCTH.2016.00019 29226097
   PubMed Web of Science ®Google Scholar
• Huang J , Mo H , Wu D , Chen X , Xu B . Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors. J Clin Oncol . 2017;35(15_suppl):e15572–e15572. doi:10.1200/JCO.2017.35.15_suppl.e15572
   Web of Science ®Google Scholar
• Lencioni R . New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin Cancer Res . 2013;19(6):1312–1314. doi:10.1158/1078-0432.CCR-12-3796 23382112
   PubMed Web of Science ®Google Scholar
• Finn RS , Qin S , Ikeda M , et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med . 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745 32402160
   PubMed Web of Science ®Google Scholar
• Xu J , Zhang Y , Jia R , et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res . 2019;25(2):515–523. doi:10.1158/1078-0432.CCR-18-2484 30348638
   PubMed Web of Science ®Google Scholar
• Yang X , Shi J , Chen X , Jiang Y , Zhao H . Efficacy of cabozantinib and nivolumab in treating hepatocellular carcinoma with RET amplification, high tumor mutational burden, and PD-L1 expression. Oncologist . 2020;25(6):470–474. doi:10.1634/theoncologist.2019-0563 32100934
   PubMed Web of Science ®Google Scholar
• Kelley RK , Abou-Alfa GK , Bendell JC , Kim TY , Sangro B . Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J Clin Oncol . 2017;35(15_suppl):4073. doi:10.1200/JCO.2017.35.15_suppl.4073
   Web of Science ®Google Scholar
• Floudas CS , Xie C , Brar G , Morelli MP , Greten TF . Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). J Clin Oncol . 2019;37(4_suppl):336. doi:10.1200/JCO.2019.37.4_suppl.336 30707056
   PubMed Web of Science ®Google Scholar
• Macek Jilkova Z , Aspord C , Decaens T . Predictive factors for response to PD-1/PD-L1 checkpoint inhibition in the field of hepatocellular carcinoma: current status and challenges. Cancers . 2019;11(10):1554. doi:10.3390/cancers11101554
   PubMed Web of Science ®Google Scholar
• Kodama K , Kawaoka T , Namba M , et al. Correlation between early tumor marker response and imaging response in patients with advanced hepatocellular carcinoma treated with lenvatinib. Oncology . 2019;97(2):75–81. doi:10.1159/000499715 31242488
   PubMed Web of Science ®Google Scholar
• Terashima T , Yamashita T , Takata N , et al. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. Hepatol Res . 2020;50(7):871–884. doi:10.1111/hepr.13505 32307874
   PubMed Web of Science ®Google Scholar
• Ohki T , Sato K , Kondo M , et al. Impact of adverse events on the progression-free survival of patients with advanced hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study. Drugs Real World Outcomes . 2020;7(2):141–149. doi:10.1007/s40801-020-00179-7 32048238
   PubMedGoogle Scholar
• Herbst RS , Soria JC , Kowanetz M , et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature . 2014;515(7528):563–567. doi:10.1038/nature14011 25428504
   PubMed Web of Science ®Google Scholar
• Hatanaka T , Kakizaki S , Nagashima T , et al. Analyses of objective response rate, progression‐free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: a multicenter retrospective study. Hepatol Res . 2019;50(3):382–395. doi:10.1111/hepr.13460 31760660
   PubMed Web of Science ®Google Scholar
• Finn R , Ryoo B , Merle P , et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol . 2020;38(3):193–202. doi:10.1200/JCO.19.01307 31790344
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB , Sangro B , Yau TC , Crocenzi TS , Melero I . Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): interim analysis of the CheckMate-040 dose escalation study. J Clin Oncol . 2016;34(15_suppl):4012. doi:10.1200/JCO.2016.34.15_suppl.4012
   Web of Science ®Google Scholar
• Wang F , Qin S , Sun X , et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol . 2020;13(1):47. doi:10.1186/s13045-020-00886-2 32393323
   PubMed Web of Science ®Google Scholar
• Kato Y , Tabata K , Kimura T , et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One . 2019;14(2):e0212513. doi:10.1371/journal.pone.0212513 30811474
   PubMed Web of Science ®Google Scholar
• Kimura T , Kato Y , Ozawa Y , Kodama K , Nomoto K . Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model. Cancer Sci . 2018;109(6):3993–4002. doi:10.1111/cas.13806 30447042
   PubMed Web of Science ®Google Scholar